Journal
CANCER RESEARCH
Volume 75, Issue 15, Pages 2969-2974Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-15-0876
Keywords
-
Categories
Funding
- U.S. Department of Health and Human Services/National Institutes of Health [5R01 CA 129377]
- NATIONAL CANCER INSTITUTE [R01CA129377] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Despite its function as an inhibitor of urokinase and tissue-type plasminogen activator (PA), PA inhibitor-1 (PAI-1) has a paradoxical protumorigenic role in cancer, promoting angiogenesis and tumor cell survival. In this review, we summarize preclinical evidence in support of the protumorigenic function of PAI-1 that has led to the testing of small-molecule PAI-1 inhibitors, initially developed as antithrombotic agents, in animal models of cancer. The review discusses the challenges and the opportunities that lay ahead to the development of efficacious and nontoxic PAI-1 inhibitors as anticancer agents. (C) 2015 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available